PARP inhibitors have transformed the treatment of ovarian cancer, particularly for patients with BRCA mutations. By blocking a DNA repair enzyme, these drugs exploit vulnerabilities in cancer cells with defective DNA repair, leading to cell death. PARP inhibitors are a growing therapeutic segment of the ovarian cancer diagnostics and therapeutics market, and they are reshaping maintenance...
Bangla